KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) Capital Expenditures (2016 - 2025)

Charles River Laboratories International has reported Capital Expenditures over the past 17 years, most recently at $89.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 17.63% year-over-year to $89.0 million; the TTM value through Dec 2025 reached $219.2 million, down 5.93%, while the annual FY2025 figure was $219.2 million, 5.93% down from the prior year.
  • Capital Expenditures for Q4 2025 was $89.0 million at Charles River Laboratories International, up from $35.6 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $106.9 million in Q2 2023 and troughed at $28.0 million in Q1 2021.
  • A 5-year average of $66.2 million and a median of $69.9 million in 2022 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 187.06% in 2022 and later plummeted 41.4% in 2024.
  • Year by year, Capital Expenditures stood at $98.8 million in 2021, then dropped by 9.87% to $89.0 million in 2022, then fell by 12.02% to $78.3 million in 2023, then fell by 3.46% to $75.6 million in 2024, then rose by 17.63% to $89.0 million in 2025.
  • Business Quant data shows Capital Expenditures for CRL at $89.0 million in Q4 2025, $35.6 million in Q3 2025, and $35.3 million in Q2 2025.